Johnson & Johnson JNJ Medtech Ortho Franchise — Restructuring

Other segment segments

Similar metrics at other companies

STEHealthcare Member — Restructuring Charges

$33.82M—

STECorporate and Other member — Restructuring expenses

$10K—

IR

IRMedical — Restructuring And Related Cost Cost Incurred To Date1

$3.2M—

STEHealthcare and Life Sciences — Restructuring expenses

$4.75M—

IR

IRMedical — Restructuring Charges

$1.73M-38.4%

TTMIOperating Segments — Restructuring Charges

$65K-93.1%

Questions, answered.

What is Johnson & Johnson's medtech ortho franchise — restructuring?

Johnson & Johnson (JNJ) reported medtech ortho franchise — restructuring of $38M in Q4 2025.

How has Johnson & Johnson's medtech ortho franchise — restructuring changed year-over-year?

Johnson & Johnson's medtech ortho franchise — restructuring increased by 15.2% year-over-year, from $33M to $38M.

What is the long-term trend for Johnson & Johnson's medtech ortho franchise — restructuring?

Over 2 years (2023 to 2025), Johnson & Johnson's medtech ortho franchise — restructuring has grown at a -26.2% compound annual growth rate (CAGR), from $279M to $152M.

What does medtech ortho franchise — restructuring mean?

The costs associated with reorganizing and improving the efficiency of the Orthopedics business segment.

How do you interpret medtech ortho franchise — restructuring?

An increase suggests active efforts to streamline operations or integrate new technologies, while a decrease may indicate the completion of a restructuring phase.

How does medtech ortho franchise — restructuring compare across companies?

Peers in the medical device industry often report these as 'restructuring charges' or 'special items' within segment-level operating expenses, making them comparable to similar transformation costs at companies like Stryker or Zimmer Biomet.